Corporate Member Update: Merck- Keytruda® (pembrolizumab): Expanded Indication
Corporate Member Update: Merck- Keytruda® (pembrolizumab): Expanded Indication
KEYTRUDA® (pembrolizumab)
January, 2022
Merck would like to inform you that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.
To read the complete expanded indication, please click here!
